Please login to the form below

Not currently logged in

PAN appoints Sarah Verhoeff as an associate director

Formerly with Euro RSCG Life (now Havas Life) in US and UK

Sarah_Verhoeff_PANSarah Vernhoeff has joined PAN as an associate director. She will report to client services director Emily Wigginton.

Vernhoeff was most recently business director at the UK office of Euro RSCG Life as it was then known, having transferred from its New York office.

She has also worked for Metamax, Rapp Collins Healthcare and McCann Relationship Marketing and was educated at University of Pennsylvania.

Jon Linscott, managing director of PAN said: “Sarah is a senior brand consultancy specialist with a proven track record for leading agency teams across multiple client businesses. We are delighted to welcome her to PAN at an exciting time in the company's development.”

Verhoeff commented: “With more than a decade's experience of healthcare marketing, both in the UK and the US, I am looking forward to working with the senior team at PAN to develop its business.”

Part of the marketing services group, Creston, London-based PAN is a founding member of the Indigenus global network. Describing itself as being about 'influential creativity', PAN won Highly Commended at the recent PM Society Advertising Awards in the Digital Sales Aid category for its Avamys campaign for GlaxoSmithKline.

12th February 2013

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company

With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...